Novavax, Inc. (NVAX)
$12.64-1.40%Close
BUYBULL · day 3
Key stats
Short interest · FINRA settlement 2026-09-30
52-week IV18.2%–298.4%
- Market cap
- $2.1B
- Beta
- 2.44
- P/E (TTM)
- -8.32
- IV-%ile
- 89
- IV ATM
- 103.7%
- Short % float
- 32.55%
- Days to cover
- 8.1
- SI change
- -7.7%
- 1W
- +12.66%
- 1M
- +36.94%
- vs SPY 1W
- +13.64%
- vs SPY 1M
- +35.08%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 21
- VALUE
- 14
- GROWTH
- 29
- GARP
- 33
- TYPE
- Growth Compounder
Composite of Value · Growth · GARP
ROIC95.9%
REV YoY-
ROE159.9%
EPS YoY-
ROA-25.9%
GROSS78
OP-55
NET-60
[VALUATION]
P/E TTM-8.32
P/E FWD456.81
SECTOR PE20.48
INDUSTRY PE13.99
P/B-10.91
P/FCF-
EV/EBITDA-10.65
EV/EBIT-
PEG2.86
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO2.33
ND/EBITDA-
BETA2.44
Company news
FAQ
- What is LOPJLB’s current signal on NVAX?
- LOPJLB’s latest quantitative signal on Novavax, Inc. (NVAX) is BUY in a BULL regime. Signals are updated daily.
- What market regime is NVAX in?
- Novavax, Inc. (NVAX) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Novavax, Inc. (NVAX) do?
- Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparti…